This text is a result of machine translation.
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Yesterday 12:13 PM
Domestic A + G listed companies will increase to 12, and the Swiss stock exchange may welcome Chinese enterprises for the first time in the second half of the year
Bad Quarter for Leading Chinese Airlines – China Southern Alone Shows Profits for Q3 2020
The three major China airlines have notified investors that the financial performance of the whole year 2020 may be seriously affected by the spread of COVID-19. Only China Southern had a positive update to share.
Nov 02, 2020 10:17 AM
Beautiful Ecology: the net profit in the first quarter increased by 24.92% to 1.9755 million yuan
Yingkang life: it is expected to lose 300 million yuan to 370 million yuan in 2021
Sanya, Hainan: suspend the operation of road passenger transport lines, tourism passenger transport, buses, etc